BioWorld

June 21, 2004

OSI's Prosidion Buying Diabetes Drug, Assets For At Least $35M

OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today) Read More

With Poor Data, Inflazyme To Drop LSAID In Asthma

FBI: Biotech Industry Not Facing Serious Problem' Of Extremists

After Reagan's Death, Pressure Mounts For Human ESC Reform

Guilford Licenses GPI 1485 To New Company Symphony

Other News To Note

Clarification

Today's news in brief

BioWorld

BioWorld briefs for June 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 6, 2025.

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...

EMA warns Ozempic linked to ‘very rare’ side effect

BioWorld

The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...

Aiatella secures €2M for AI-based cardiovascular imaging tech

BioWorld MedTech

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...